Company intelligence / Profile preview

Medici

Yongin-si, Gyeonggi-do, South Koreamedici.ca ↗

Ownership: Private
Development stage: Commercial

Overview

MediciBIO has developed a proprietary next-generation lipid nanoparticle platform for efficient delivery of gene therapeutics, including siRNA, antisense oligonucleotides, mRNA, and self-amplifying mRNA. The company focuses on first-in-class/orphan drugs targeting genetic and rare diseases in ophthalmology, cancer, and neurology. It has received multiple government grants and patent registrations but has not yet reported results from advanced clinical trials.

Therapeutic areas: OncologyOphthalmologyRare DiseasesNeurology
Modalities: Antisense oligonucleotideSmall interfering RNAmRNA-based drugsSelf-amplifying mRNA (samRNA)Lipid nanoparticle delivery therapy
Industry: Biotech

Partnerships

Coalition for Epidemic Preparedness Innovations (CEPI) with Chungbuk National University and MicrouniKorean Drug Development Fund support

Beyond the preview

Go deeper on Medici.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medici.

Explore the full profile